FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2091259554> ?p ?o ?g. }

• W2091259554 endingPage "31" @default.
• W2091259554 startingPage "31" @default.
• W2091259554 abstract "Increased concentrations of inflammatory biomarkers predict antidepressant nonresponse, and inflammatory cytokines can sabotage and circumvent the mechanisms of action of conventional antidepressants.To determine whether inhibition of the inflammatory cytokine tumor necrosis factor (TNF) reduces depressive symptoms in patients with treatment-resistant depression and whether an increase in baseline plasma inflammatory biomarkers, including high-sensitivity C-reactive protein (hs-CRP), TNF, and its soluble receptors, predicts treatment response.Double-blind, placebo-controlled, randomized clinical trial.Outpatient infusion center at Emory University in Atlanta, Georgia.A total of 60 medically stable outpatients with major depression who were either on a consistent antidepressant regimen (n = 37) or medication-free (n = 23) for 4 weeks or more and who were moderately resistant to treatment as determined by the Massachusetts General Hospital Staging method.Three infusions of the TNF antagonist infliximab (5 mg/kg) (n = 30) or placebo (n = 30) at baseline and weeks 2 and 6 of a 12-week trial.The 17-item Hamilton Scale for Depression (HAM-D) scores.No overall difference in change of HAM-D scores between treatment groups across time was found. However, there was a significant interaction between treatment, time, and log baseline hs-CRP concentration (P = .01), with change in HAM-D scores (baseline to week 12) favoring infliximab-treated patients at a baseline hs-CRP concentration greater than 5 mg/L and favoring placebo-treated patients at a baseline hs-CRP concentration of 5 mg/L or less. Exploratory analyses focusing on patients with a baseline hs-CRP concentration greater than 5 mg/L revealed a treatment response (≥50% reduction in HAM-D score at any point during treatment) of 62% (8 of 13 patients) in infliximab-treated patients vs 33% (3 of 9 patients) in placebo-treated patients (P = .19). Baseline concentrations of TNF and its soluble receptors were significantly higher in infliximab-treated responders vs nonresponders (P < .05), and infliximab-treated responders exhibited significantly greater decreases in hs-CRP from baseline to week 12 compared with placebo-treated responders (P < .01). Dropouts and adverse events were limited and did not differ between groups.This proof-of-concept study suggests that TNF antagonism does not have generalized efficacy in treatment-resistant depression but may improve depressive symptoms in patients with high baseline inflammatory biomarkers.clinicaltrials.gov Identifier: NCT00463580." @default.
• W2091259554 created "2016-06-24" @default.
• W2091259554 creator A5002577290 @default.
• W2091259554 creator A5024726266 @default.
• W2091259554 creator A5048809059 @default.
• W2091259554 creator A5053081903 @default.
• W2091259554 creator A5059583278 @default.
• W2091259554 creator A5076322374 @default.
• W2091259554 creator A5082742034 @default.
• W2091259554 creator A5085475946 @default.
• W2091259554 date "2013-01-01" @default.
• W2091259554 modified "2023-10-14" @default.
• W2091259554 title "A Randomized Controlled Trial of the Tumor Necrosis Factor Antagonist Infliximab for Treatment-Resistant Depression" @default.
• W2091259554 cites W1591586719 @default.
• W2091259554 cites W1729764133 @default.
• W2091259554 cites W1847168837 @default.
• W2091259554 cites W1851597206 @default.
• W2091259554 cites W1978836263 @default.
• W2091259554 cites W1981907384 @default.
• W2091259554 cites W1985329135 @default.
• W2091259554 cites W1985438873 @default.
• W2091259554 cites W1989369404 @default.
• W2091259554 cites W1996454121 @default.
• W2091259554 cites W1996589984 @default.
• W2091259554 cites W1996826305 @default.
• W2091259554 cites W1998878650 @default.
• W2091259554 cites W2001997781 @default.
• W2091259554 cites W2002537642 @default.
• W2091259554 cites W2007116949 @default.
• W2091259554 cites W2013555477 @default.
• W2091259554 cites W2013887960 @default.
• W2091259554 cites W2015458228 @default.
• W2091259554 cites W2018613168 @default.
• W2091259554 cites W2025026106 @default.
• W2091259554 cites W2025629977 @default.
• W2091259554 cites W2031062821 @default.
• W2091259554 cites W2034630933 @default.
• W2091259554 cites W2042046176 @default.
• W2091259554 cites W2042944469 @default.
• W2091259554 cites W2043087631 @default.
• W2091259554 cites W2046572145 @default.
• W2091259554 cites W2050074023 @default.
• W2091259554 cites W2050961629 @default.
• W2091259554 cites W2053020615 @default.
• W2091259554 cites W2054381792 @default.
• W2091259554 cites W2059416963 @default.
• W2091259554 cites W2060345189 @default.
• W2091259554 cites W2060709606 @default.
• W2091259554 cites W2060913403 @default.
• W2091259554 cites W2064412851 @default.
• W2091259554 cites W2065313926 @default.
• W2091259554 cites W2068103783 @default.
• W2091259554 cites W2068297463 @default.
• W2091259554 cites W2073134404 @default.
• W2091259554 cites W2078927723 @default.
• W2091259554 cites W2081756664 @default.
• W2091259554 cites W2090685459 @default.
• W2091259554 cites W2091732046 @default.
• W2091259554 cites W2098108268 @default.
• W2091259554 cites W2099516158 @default.
• W2091259554 cites W2104205224 @default.
• W2091259554 cites W2114613490 @default.
• W2091259554 cites W2114879270 @default.
• W2091259554 cites W2120306544 @default.
• W2091259554 cites W2126365703 @default.
• W2091259554 cites W2128416931 @default.
• W2091259554 cites W2132324173 @default.
• W2091259554 cites W2136907769 @default.
• W2091259554 cites W2138512906 @default.
• W2091259554 cites W2138970660 @default.
• W2091259554 cites W2142133137 @default.
• W2091259554 cites W2143247032 @default.
• W2091259554 cites W2145857851 @default.
• W2091259554 cites W2155574232 @default.
• W2091259554 cites W2161296293 @default.
• W2091259554 cites W2163092745 @default.
• W2091259554 cites W2163146861 @default.
• W2091259554 cites W2163741803 @default.
• W2091259554 cites W2164423986 @default.
• W2091259554 cites W2168911501 @default.
• W2091259554 cites W2172218978 @default.
• W2091259554 cites W2314684025 @default.
• W2091259554 cites W30166364 @default.
• W2091259554 cites W72976067 @default.
• W2091259554 doi "https://doi.org/10.1001/2013.jamapsychiatry.4" @default.
• W2091259554 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4015348" @default.
• W2091259554 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22945416" @default.
• W2091259554 hasPublicationYear "2013" @default.
• W2091259554 type Work @default.
• W2091259554 sameAs 2091259554 @default.
• W2091259554 citedByCount "1212" @default.
• W2091259554 countsByYear W20912595542012 @default.
• W2091259554 countsByYear W20912595542013 @default.
• W2091259554 countsByYear W20912595542014 @default.
• W2091259554 countsByYear W20912595542015 @default.
• W2091259554 countsByYear W20912595542016 @default.
• W2091259554 countsByYear W20912595542017 @default.
• W2091259554 countsByYear W20912595542018 @default.

• next